Study checks if antibiotic dosing hits the mark in ICU sepsis patients
NCT ID NCT02888470
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study examines whether intensive care unit (ICU) patients being treated for sepsis receive aminoglycoside antibiotics at doses that achieve the recommended peak concentration in the blood. Researchers will measure drug levels after the first and later doses in about 90 adults. The goal is to understand how often current dosing practices hit the target, which could help improve antibiotic therapy in critically ill patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
aminoglycoside antibiotics
What this could lead to
If the study finds that current dosing often misses the target, it could lead to better dosing guidelines for ICU patients with sepsis.
What could go wrong
This is an observational study that only measures current practice, not a test of a new treatment. It cannot prove that changing doses improves outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEPSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de Nîmes
Nîmes, Gard, 30029, France